DNA
Ginkgo Bioworks Holdings, Inc.
NYSE · Healthcare · Biotechnology · US
$6.95
+0.00%Margins
Gross margin
80.1%
EBITDA margin
-187.0%
EBIT margin
-259.9%
Net margin
-260.0%
FCF margin
-170.0%
-69.2%
Return on equity
-29.4%
Return on assets
-35.3%
Return on invested capital
0.11x
Asset turnover
-$170.2M
Cash from operations
$4.49
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026